Abstract. ) is a cytokine with a critical role in regulating the immune response to infectious disease. Studies have indicated that polymorphisms in the IL-6 gene may be linked to hepatitis B virus (HBV) infection. The purpose of the present study was to examine the association among IL-6 SNPs and haplotypes with HBV infection risk in a Malaysian population. A total of 1,246 Malaysian subjects with and without chronic hepatitis B were recruited for this study. Three IL-6 polymorphisms (rs2069837, rs1800796 and rs2066992) were genotyped using a Sequenom MassARRAY ® platform. The results suggested that GC and CC genotypes of rs1800796 as well as GT and TT genotypes of rs2066992 were associated with protection against HBV infection (P<0.001). Furthermore, haplotypes GG and CT exhibited a significant association with protection against HBV (P=0.003 and =0.005, respectively); and haplotypes GG and CT exhibited a significant association with clearance of HBV infection (P=0.035 and =0.037, respectively). The present study indicates that two IL-6 SNPs (rs1800796 and rs2066992) are associated with clearance of chronic HBV or protection against HBV infection at allelic, genotypic and haplotypic levels.
Introduction
Hepatitis B virus (HBV) infection is a potentially severe disease affecting ~2 billion people worldwide (1, 2) . It was reported by the World Health Organization in 2015 that an estimated ~240 million individuals are chronically infected with the HBV virus and that 780,000 mortalities occur per year due to the consequences of HBV infection including liver cirrhosis (LC) and hepatocellular carcinoma (HCC) (3) . The regions with high endemic rates of HBV infection primarily include Southeast Asia, the Western Pacific and Africa, in which incidences of more than 8% of the population have been reported (4) . Thus HBV infection is a major public health issue, particularly since it exhibits variable epidemiology between different populations (4) .
Numerous studies have revealed complex interactions between the host (genetic background and immune response), the virus and the environment, which may contribute to the outcomes of HBV infection (5) (6) (7) . In particular, familial and twin studies have confirmed a significant role of host genetic factors in the persistence of HBV infection (8, 9) .
Several studies, including genome wide association studies (GWAS), have revealed that single nucleotide polymorphisms (SNPs) in certain genes influence the outcomes of HBV infection (10) (11) (12) (13) (14) (15) (16) . Nevertheless, there are geographical and ethnic differences between these genetic factors and the outcomes of HBV infection (17, 18) .
Interleukin-6 (IL-6) is among the GWAS-identified genes and has been reported to be linked to susceptibility to HBV infection, clearance rate of HBV and also progression to severe liver disease (19) (20) (21) . IL-6 is a cytokine with a vital role in the regulation of immune reactions in numerous target cells including hepatocytes (19) . Previous data has indicated that host innate immunity serves a crucial role in controlling HBV infection and that IL-6 is a main factor involved in regulation of the innate immune response (19) . It has been reported that IL-6 derived from activated monocytes serves a significant role in stimulating the immune response required for viral control (22) . However, as a mediator of inflammation, it may also be involved in the progression of HBV-associated cirrhosis and HCC (22 (24) . Diagnoses of HCC were based on radiological evidence of liver mass with arterial hypervascularity and washout in the venous-delayed phase on dynamic imaging and/or by liver histology (25) . Patients with other possible causes of liver disease including primary biliary cirrhosis, Wilson's disease, hepatitis C infection, autoimmune hepatitis, hemochromatosis and α-1 anti-trypsin deficiency were excluded from the study. The study protocol was approved by the Medical Ethics Committee of the University of Malaya Medical Centre (ref. no. 938.42). Ethnicities of the subjects were confirmed by a self-report. Signed and dated informed consent was obtained from all of the subjects.
Selection of SNPs.
To examine whether variants in the IL-6 gene are capable of affecting HBV infection risk in a Malaysian population, three IL-6 polymorphisms (rs2069837 A>G, rs1800796 G>C and rs2066992 G>T) were selected based on the criteria of previous HBV studies (19) (20) (21) in other populations involving candidate genes with minor allele frequency >0.1 from the NCBI online database (https://www.ncbi.nlm.nih.gov).
Genotyping of IL-6 SNPs. Genomic DNA was extracted from buffy coat (isolated from 4 ml peripheral blood following collection in anticoagulant tubes and centrifugation at 1,600 x g for 10 min at room temperature) using a GeneAll @ Exgene™ DNA purification kit (GeneAll Biotechnology, Co., Ltd., Seoul, South Korea) according to the manufacturer's instructions. The 3 selected IL-6 polymorphisms (rs2069837, rs1800796 and rs2066992) were genotyped using a Sequenom MassARRAY ® platform (Sequenom, Inc., San Diego, CA, USA) according to relevant guidelines (26) . A volume of 1 µl genomic DNA with a mean average concentration between 10-20 ng/µl was used in each amplification reaction. A blank and five duplicates were presented for quality control, and were excluded if any of the following occurred: assay with >10% call rate in blank checks; >25% call rate within the blank control; <99.5% concordance in duplicate checks and assay with <80% call rate in the same SpectroCHIP.
Statistical analysis. Data analysis was performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). The allele and genotype distributions of the IL-6 SNPs between the groups were assessed by χ 2 test. Logistic regression was performed to determine the association of IL-6 SNPs with (i) chronic HBV infection and disease progression, (ii) between chronic and resolved HBV subjects and (iii) between chronic HBV patients and healthy controls. Odd ratios (ORs) with 95% confidence intervals (CI) were calculated following correction for confounding factors including sex and age. The SNPs were tested for deviation from Hardy-Weinberg equilibrium (HWE). Subgroup analysis based on ethnicity of allele and genotype distribution of the IL-6 SNPs was not performed due to the small sample size of each ethnic group.
Additionally, construction of linkage disequilibrium (LD) blocks and haplotype analysis were performed using Haploview 4.2 software (Broad Institute, Cambridge, MA, USA). Haplotype frequencies were compared between (i) chronic HBV cases with and without progression to LC/HCC, (ii) chronic and resolved HBV subjects and (iii) between chronic HBV patients and healthy controls, by calculating the permutation P-values created using χ 2 statistics with one degree of freedom. P<0.05 was considered to indicate statistical significance. The data were presented as frequency (percentage) or median (range).
Results
General characteristics of subjects. The demographics of the study participants are listed in Table I . The median ages of chronic HBV patients without LC/HCC, chronic HBV patients with LC/HCC, HBV-resolved subjects and healthy controls were 54 (range, 37-69), 66 (range, 51-79), 31 (range, 20-42) and 33 (range, 19-47), respectively.
IL-6 allele frequencies.
The allelic distributions and frequencies of the 3 IL-6 SNPs amongst chronic HBV patients, HBV-resolved subjects and healthy controls are presented in Table II . A significant difference in the allelic frequencies of IL-6 rs2069837, rs1800796 and rs2066992 was observed between chronic HBV patients and healthy controls (OR=0.60, 95% CI=0.47-0.78, P<0.001; OR=0.40, 95% CI: 0.34-0.48, P<0.001; and OR=0.40, 95% CI: 0.33-0.47, P<0.001, respectively). For rs1800796 and rs2066992, the frequency of allele G (mutate allele) among healthy controls (0.303) was higher than that among chronic HBV patients (0.258 for rs1800796 and 0.265 for rs2066992). There were no significant differences in allelic frequencies for rs2069837, rs1800796 and rs2066992 between chronic HBV cases with and without LC/HCC or between chronic HBV Data are presented as frequency (percentage). OR and 95% CI were calculated using logistic regression, adjusted for sex and age. P-values were determined using χ 2 test. IL-6, interleukin-6; HBV, hepatitis B virus; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval. patients and HBV-resolved subjects; although association was indicated for IL-6 rs2066992 between chronic HBV patients and HBV-resolved HBV subjects (P=0.053).
IL-6 genotype frequencies. The genotypic distributions of the 3 IL-6
SNPs among chronic HBV patients, HBV-resolved subjects and healthy controls are presented in Table III .001 for TT genotype). There were no significant differences in the genotypic frequencies of rs2069837, rs1800796 and rs2066992 between chronic HBV cases with and without LC/HCC or between chronic HBV patients and HBV-resolved subjects. The genotype distribution of rs2069837, rs1800796 and rs2066992 were in HWE (P>0.05 for each) except for rs2069837 in chronic HBV-related LC/HCC cases (P=0.036) and the healthy control group (P<0.001).
IL-6 haplotype frequencies.
The results of three haplotype analyses performed between (i) chronic HBV cases with and without LC/HCC, (ii) chronic HBV patients and HBV-resolved subjects and (iii) chronic HBV patients and healthy controls are presented in Table IV . The haplotype combination, CT and GG, was generated between IL6 rs1800796 and rs2066992. IL6 rs2069837 was excluded from analysis due to deviation from HWE. Significant associations with strong LD (D'=0.98) was observed of haplotypes CT and GG in the comparison of chronic HBV patients vs. healthy controls (P=0.005, frequency 0.709 and P=0.003, frequency 0.282, respectively). Similarly, the haplotype results on comparing the chronic HBV and HBV-resolved groups indicated significant association with strong LD (D'=0.99).
Haplotype CT (P=0.037, frequency 0.720) and haplotype GG (P=0.035, frequency 0.269) were significantly associated with clearance of the HBV virus. Although the IL6 rs1800796 and rs2066992 SNPs between chronic HBV cases with and without LC/HCC were in strong LD (D'=0.99), there were no significant associations with progression of chronic HBV infection. The LD pattern in the three comparisons is depicted in Fig. 1 . Table IV . Haplotype analysis of IL-6 rs1800796 and rs2066992 association between chronic HBV patients, healthy controls and HBV-resolved subjects. 
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Discussion
In the present study, two SNPs (rs1800796 and rs2066992) in the IL-6 gene were identified to be associated with protection against HBV infection in a Malaysian population. It was observed that the G allele in both SNPs (rs1800796 and rs2066992) may have a significant protective role against HBV infection. The results also indicated that the GG and CT haplotypes of IL6 rs1800796 and rs2066992 were associated with protection against HBV infection (in comparison with healthy controls) as well as with clearance of HBV (in comparison with HBV-resolved subjects). For IL-6 rs1800796, the genotypes GG and GC containing the protective allele G were more frequently identified among healthy controls as compared with chronic HBV patients. Saxena et al (27) similarly reported that the GG genotype of IL-6 rs1800796 was more frequent in healthy controls as compared with chronic HBV patients. However, for IL-6 rs2066992, genotypes GG and GT containing the protective allele G were predominant among healthy controls as compared with chronic HBV patients (27) .
There was no significant difference between the ethnicity and the study subjects. Nonetheless, the study had higher number of Chinese participants compared to Malays and Indian. This is probably due to the fact that CHB infection is generally common among Chinese in Malaysia (28) Host genetic background and its interaction with HBV may affect the outcomes of long-term infection (29) . IL-6 has been demonstrated to be involved in HBV infection in vitro and in vivo (30) . Emerging data has revealed that the IL-6 polymorphism rs1800796 may be associated with differences in the outcomes of hepatitis B infection including progression to LC/HCC as well as clearance of the virus (19, 20) . It is speculated that genetic alteration in the IL-6 gene has an effect on immune dysfunction, which may be involved in the pathogenesis of HBV infection (31) . It has been reported that variation in the IL-6 gene resulting in functional alteration, which may be responsible for changes in the levels of transcription, protein expression and serum IL-6, were correlated with HBV disease outcomes (22) . Furthermore, it has been indicated that IL-6 contributes to the interaction between the hepatocyte plasma membrane and the HBV particle (32); HBV could then bind to the preS1 domain on human hepatocytes, mediating HBV infection (31) . As a result of activating these signaling pathways, IL-6 may increase the activity of the HBV enhancer 1 to control the expression of HBV X protein and the replication of HBV (32) . A study by Chou et al (33) reported that IL-6 in hepatoma cells promoted HBV transcription by activating signal transducer and activator of transcription 3, which may interact with hepatocyte nuclear factor 3 bound to the HBV enhancer.
In the present study, the rs1800796-G allele (mutant allele) was identified to be the minor allele compared with the C allele (wild-type allele) among healthy controls. A similar result was observed for rs2066992-G allele (mutant allele) as compared with the T allele (wild-type allele) in the same group. In addition, it was identified that rs1800796 and rs2066992 genotypes were significantly associated with protection from HBV infection. However, no association was observed on comparison between chronic HBV and HBV-resolved subjects or between chronic HBV cases with and without LC/HCC. This is contradictory to a study by Lu et al (19) , which reported that genetic variation in the SNP IL-6-572 C/G may be associated with clearance of HBV infection. Furthermore, the results of another study revealed that genetic variation in the SNP IL-6-572 may be associated with HCC incidence in males (34) .
In the present study no significant difference was identified in the genotype/allele frequencies of rs2069837, rs1800796 and rs2066992 between chronic HBV patients with and without LC/HCC. Hence, these SNPs are likely not associated with progression to liver disease in HBV-infected patients in the Malaysian population. Furthermore, it was observed that these IL-6 variants were not associated with clearance of HBV infection. Similarly, Park et al (35) reported that IL-6 variants were not associated with HBV infection or the progression of HBV-associated liver disease.
Considering that haplotypes may be more effective markers of association regarding disease-linked genes than SNPs (36) , the association of IL-6 haplotypes with progression and clearance of HBV infection was examined. All three SNPs are common variants including the functional polymorphism of the IL-6 promoter (rs1800796) and the SNPs in the intron 2 region (rs2069837 and rs2066992) (37). Significant associations were observed for haplotypes GG and CT on comparison of individuals with chronic HBV with healthy controls and HBV-resolved subjects. Notably, the haplotype results indicated that the wild-type haplotype (GG) had higher frequency in healthy controls as compared with chronic HBV patients. Similarly, the haplotype GG had higher frequency in HBV-resolved patients as compared with chronic HBV patients. However, the haplotype CT exhibited a significant association with chronic HBV as compared with healthy controls and HBV-resolved subjects, with the highest frequency observed in chronic HBV patients.
The present study to the best of our knowledge is the first to investigate the association among IL-6 SNPs and HBV infection risk in a Malaysian population. Nonetheless, the present study had limitations with regard to functional insights into the role of IL-6 in HBV infection. Thus, functional studies using mammalian cell lines are required in order to investigate the transcriptional activities of the IL-6 SNPs.
In conclusion, association was identified between polymorphic variants of the wild-type alleles of rs1800796 and rs2066992 of IL-6 and protection from HBV infection among a Malaysian population. Similarly, Lu et al reported that allele G was associated with the natural elimination of HBV infection (19) . Furthermore, study has indicated that the G allele is associated with significantly elevated circulating levels of IL-6 (27) . These findings are consistent with current results and support the apparent protective role of allele G in HBV infection. It was also indicated that haplotypes GG and CT of IL-6 may have a significant protective role with regard to hepatitis B disease outcomes in Malaysian individuals. However, functional studies and more diverse cohorts are required to provide wider insight into the role of IL-6 in HBV infection.
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